- Home
- NBBK vs SLN Comparison
NBBK vs SLN Comparison
Compare NBBK & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- SLN
- Stock Information
- Founded
- NBBK 1892
- SLN 1994
- Country
- NBBK United States
- SLN United Kingdom
- Employees
- NBBK N/A
- SLN N/A
- Industry
- NBBK
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- SLN Health Care
- Exchange
- NBBK Nasdaq
- SLN Nasdaq
- Market Cap
- NBBK 783.2M
- SLN 842.4M
- IPO Year
- NBBK N/A
- SLN N/A
- Fundamental
- Price
- NBBK $20.30
- SLN $7.22
- Analyst Decision
- NBBK Buy
- SLN Strong Buy
- Analyst Count
- NBBK 1
- SLN 4
- Target Price
- NBBK $22.00
- SLN $61.50
- AVG Volume (30 Days)
- NBBK 160.3K
- SLN 529.5K
- Earning Date
- NBBK 10-30-2024
- SLN 11-14-2024
- Dividend Yield
- NBBK N/A
- SLN N/A
- EPS Growth
- NBBK N/A
- SLN N/A
- EPS
- NBBK 0.30
- SLN N/A
- Revenue
- NBBK $146,994,000.00
- SLN $21,773,221.00
- Revenue This Year
- NBBK N/A
- SLN N/A
- Revenue Next Year
- NBBK N/A
- SLN $104.98
- P/E Ratio
- NBBK $67.20
- SLN N/A
- Revenue Growth
- NBBK 11.94
- SLN N/A
- 52 Week Low
- NBBK $13.10
- SLN $5.81
- 52 Week High
- NBBK $20.98
- SLN $27.72
- Technical
- Relative Strength Index (RSI)
- NBBK 58.58
- SLN 7.70
- Support Level
- NBBK $19.51
- SLN $5.81
- Resistance Level
- NBBK $20.97
- SLN $18.24
- Average True Range (ATR)
- NBBK 0.54
- SLN 1.35
- MACD
- NBBK -0.04
- SLN -1.15
- Stochastic Oscillator
- NBBK 65.76
- SLN 7.94
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.